B. Metzler seel. Sohn & Co. AG Invests $982,000 in Illumina, Inc. $ILMN

B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 5,587 shares of the life sciences company's stock, valued at approximately $982,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. HighPoint Advisor Group LLC lifted its holdings in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company's stock valued at $291,000 after purchasing an additional 80 shares during the last quarter. Elevation Wealth Partners LLC lifted its position in Illumina by 52.5% during the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company's stock worth $43,000 after purchasing an additional 84 shares during the period. Meeder Advisory Services Inc. raised its position in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company's stock valued at $348,000 after purchasing an additional 85 shares in the last quarter. Toronto Dominion Bank lifted its position in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company's stock worth $4,407,000 after buying an additional 92 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its holdings in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company's stock valued at $333,000 after purchasing an additional 96 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,095,958 shares of company stock valued at $401,720,974 in the last quarter. Insiders own 2.90% of the company's stock.

Illumina Stock Performance

Shares of ILMN opened at $219.40 on Monday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $220.43. The stock's 50-day simple moving average is $188.01 and its 200 day simple moving average is $152.52. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a market capitalization of $33.13 billion, a price-to-earnings ratio of 40.93, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Analyst Upgrades and Downgrades

Several equities analysts have commented on ILMN shares. Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research report on Wednesday, August 5th. Guggenheim boosted their target price on shares of Illumina from $200.00 to $226.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Evercore reissued an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Weiss Ratings raised Illumina from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, June 3rd. Finally, Citigroup raised their target price on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Illumina has a consensus rating of "Hold" and an average target price of $188.40.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source